Biofil Chemicals Pharmaceuticals Ltd vs Shree Ganesh Biotech India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Biofil Chemicals & Pharmaceuticals Ltd is ₹ 33.18 as of 05 May 15:30 . The P/E Ratio of Biofil Chemicals & Pharmaceuticals Ltd changed from 86.4 on March 2021 to 121 on March 2025 . This represents a CAGR of 6.97% over 5 yearsThe P/E Ratio of Shree Ganesh Biotech India Ltd changed from 740.6 on March 2021 to 90 on March 2025 . This represents a CAGR of -34.40% over 5 years The Market Cap of Biofil Chemicals & Pharmaceuticals Ltd changed from ₹ 106.81 crore on March 2021 to ₹ 66.92 crore on March 2025 . This represents a CAGR of -8.93% over 5 yearsThe Market Cap of Shree Ganesh Biotech India Ltd changed from ₹ 236.18 crore on March 2021 to ₹ 35.88 crore on March 2025 . This represents a CAGR of -31.40% over 5 years The revenue of Biofil Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 0.93 crore as compare to the Sep '25 revenue of ₹ 13.6 crore. This represent the decline of -93.16% The revenue of Shree Ganesh Biotech India Ltd for the Dec '25 is ₹ 1.07 crore as compare to the Sep '25 revenue of ₹ 1.18 crore. This represent the decline of -9.32% The ebitda of Biofil Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 0.17 crore as compare to the Sep '25 ebitda of ₹ 0.18 crore. This represent the decline of -5.56% The ebitda of Shree Ganesh Biotech India Ltd for the Dec '25 is ₹ 0.32 crore as compare to the Sep '25 ebitda of ₹ 0.01 crore. This represent the growth of 3100% The net profit of Biofil Chemicals & Pharmaceuticals Ltd changed from ₹ 0.17 crore to ₹ 0.08 crore over 7 quarters. This represents a CAGR of -35.00% The net profit of Shree Ganesh Biotech India Ltd changed from ₹ 0.24 crore to ₹ 0.32 crore over 7 quarters. This represents a CAGR of 17.87% The Dividend Payout of Biofil Chemicals & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Shree Ganesh Biotech India Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Biofil Chemicals & Pharmaceuticals Ltd

Biofil Chemicals & Pharmaceuticals Limited (BCPL) was incorporated as a Private Limited Company on 4 Jan.'85 for manufacturing and trading of Pharmaceuticals products.
Later on, the Company was converted into a Public Limited Company on 7 May '92.
The Company deals in providing job work facility in respect of manufacturing of pharmaceuticals drug.
It runs the business via two unit viz Pharmaceutical Division & Chemicals Division. In Feb.'96, the company had come out with a rights-cum-public issue at a premium of Rs 7.50 and at a premium of Rs 12.50 respectively, both aggregating Rs 23.21 cr, to part-finance its expansion and diversification into bulk drugs and pharmaceutical formulations.
The company currently manufactures pharmaceutical formulations like injections, capsules, eye-drops and dry syrups at its plant located in Indore.

About Shree Ganesh Biotech India Ltd

Shree Ganesh Biotech India Limited was incorporated on September 2, 1982, as 'S.P. Commercial Co. Limited' with the Registrar of Companies, West Bengal.
The Company got the Certificate of Commencement of Business on September 14, 1982.
The Company was incorporated with an object to carry on the business of builders, Contractors and to deal in property and also to do investment and finance business. In 2010, pursuant to a Scheme of Amalgamation, Shree Ganesh Bio-Tech (India) Private Limited was merged with S.P. Commercial Co. Limited pursuant to the order of the Hon'ble High at Calcutta dated February 15, 2010.
The entire business of Shree Ganesh Bio-Tech (India) Private Limited consisting of trading and distribution of seeds were transferred to S.P. Commercial Co. Limited.
Subsequently, Shree Ganesh Bio-Tech (India) Private Limited was dissolved pursuant to the said Scheme of Amalgamation and the name of the Company was changed to Shree Ganesh Bio-Tech (India) Limited.

FAQs for the comparison of Biofil Chemicals & Pharmaceuticals Ltd and Shree Ganesh Biotech India Ltd

Which company has a larger market capitalization, Biofil Chemicals & Pharmaceuticals Ltd or Shree Ganesh Biotech India Ltd?

Market cap of Biofil Chemicals & Pharmaceuticals Ltd is 53 Cr while Market cap of Shree Ganesh Biotech India Ltd is 25 Cr

What are the key factors driving the stock performance of Biofil Chemicals & Pharmaceuticals Ltd and Shree Ganesh Biotech India Ltd?

The stock performance of Biofil Chemicals & Pharmaceuticals Ltd and Shree Ganesh Biotech India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biofil Chemicals & Pharmaceuticals Ltd and Shree Ganesh Biotech India Ltd?

As of May 5, 2026, the Biofil Chemicals & Pharmaceuticals Ltd stock price is INR ₹33.18. On the other hand, Shree Ganesh Biotech India Ltd stock price is INR ₹0.63.

How do dividend payouts of Biofil Chemicals & Pharmaceuticals Ltd and Shree Ganesh Biotech India Ltd compare?

To compare the dividend payouts of Biofil Chemicals & Pharmaceuticals Ltd and Shree Ganesh Biotech India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.